zh-twzhen
zh-twzhen

News

2026

Date

Title

2026-03-12

EU NB issued the EU market approval for Bonvadis that grants marketing authorization across all 27 EU member states for acute and chronic wounds, and scar management.

>
2026-03-05

Oneness Board of Directors resolved to convene the Annual Shareholders’ Meeting of 2026. (additional matters)

>
2026-03-05

The board of directors of Oneness approved a resolution on issuance of the Restricted Stock Awards (RSA) of 2026.

>
2026-03-05

The board of directors of the Company approved a resolution on the 1st issue of the employee stock option certificate of 2026.

>
2026-03-05

The Board of Directors resolved not to distribute dividends.

>
2026-03-05

The Company’s 2025 consolidated financial statements have been approved by the Board of Directors

>
2026-02-24

A Phase 1 clinical trial of SNS851 has been approved by Australia HREC and acknowledged by Australia TGA.

>
2026-02-23

News-Global Recognition for Microbio Group Microbio, Oneness Biotech, and Diamond BioFund are Included in the 2026 S&P Global Sustainability Yearbook

>
2026-02-22

Bonvadis topical cream received medical device marketing authorization approval for all indications in wounds by INVIMA Colombia.

>
2026-02-07

Oneness ON101 cream promotes healing of an essential thrombocythemia–associated toe ulcer, with findings published in the SCI journal, Journal of Wound Care

>
2026-01-31

The medical device registration application of Bonvadis for all indications of wounds has been accepted by INVIMA Colombia.

>
2026-01-13

Oneness Board of Directors resolved to convene the Annual Shareholders’ Meeting of 2026.

>
2026-01-05

Bonvadis topical cream received medical device marketing authorization approval for all indications in wounds by EDA Egypt.

>